ClinicalTrials.gg
CompletedNCT02832492Updated Aug 4, 2022

The Prognostic Value of Pupil Near Response in UWS Patients

An observational study in Vegetative State, sponsored by Wentao Zeng. Completed. Open to participants aged 6 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-08-04.

Sponsored by Wentao Zeng · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
6 Years to 85 Years
Sex
All
01

Study summary

Previous studies suggest that the stimulus of pupil near response (PNR) may be a conscious perception of a blurred image. Moreover, PNR is a reflex that can be objectively observed and with no motor output, suggesting it might be a more convenient index for consciousness evaluation and consciousness recovery in patients with disorders of consciousness (DOC). We thus hypothesized that PNR+ patients (patients show PNR during the assessment) would have better prognosis than PNR- patients (patients fail to show PNR during the assessment).Based on this hypotheis, researchers will assess pupil near response in patients with unresponsive wakefulness syndrome (UWS) and compare the prognosis difference between PNR+ patients and PNR- patients to assess its prognosis value.

Read the detailed description

PNR assessments will be conducted in patients with Unresponsive Wakefulness Syndrome (UWS) diagnosed by the Coma recovery scale-revised (CRS-R).An objective index,the ratio of pupillary constriction (pupil diameter change after a stimulus presentation divided by the resting state pupil diameter) will be used as the measure of PNR's presence (positive results indicate the presence of PNR,whereas negative results indicate the absence of PNR).According to the presence of PNR,patients will be divided into 2 groups,one includes patients who show PNR during the PNR assessment (PNR+),the other includes patients who fail to show PNR during the PNR assessment(PNR-).3 months later,a follow-up will be conducted to obtain their prognosis in the form of another CRS-R assessment.Patients diagnosed as Minimally Conscious State (MCS) will be considered as favourable prognosis,patients diagnosed as UWS will be considered as unfavourable prognosis.Their prognosis difference will then be compared to see PNR's effect on their prognosis (consciousness recovery). And for they couldn't show conscious visual behaviors (visual behaviors in CRS-R which indicate MCS) in the first CRS-R,their difference between visual prognosis (difference between each group's proportion of patients showing conscious visual behavior diagnosed by CRS-R in the follow up) will be compared to see PNR's capability to predict prognosis in patients without voluntary eye movements (conscious visual behaviors in CRS-R require voluntary eye movements).

Researchers expect to see the PNR+ group have better prognosis in both comparison.

02

Conditions studied

  • Vegetative State

Keywords

  • disorders of consciousness
  • unresponsive wakefulness syndrome
  • pupil near response
  • prognosis of consciousness recovery
03

In context

Persistent Vegetative State

88 studies on the registry are indexed under Persistent Vegetative State; 20 are open to participants now.

This study's enrollment of 20 is below the median of 80 across 31 observational studies indexed under Persistent Vegetative State.

Browse Persistent Vegetative State studies →

Lead sponsor

This is the only study on the registry with Wentao Zeng as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients who has been diagnosed as unresponsive wakefulness syndrome by CRS-R before this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • unresponsive wakefulness syndrome (diagnosed by CRS-R)
  • normal or corrected to normal vision before the incidence (myopia did not exceed 300 degrees Fahrenheit, farsightedness was less than + 2.00 d)
  • positive pupil light reflex.

Exclusion criteria

Exclusion Criteria:

  • nystagmus and drooping eyelids
  • unstable vital signs
  • under sedation during PNR test.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • PNR+

    Patients who will show pupil near response during PNR assessment.

    Behavioral: pupil near response

  • PNR-

    Patients who will not show pupil near response during PNR assessment.

    Behavioral: pupil near response

Interventions

  • Behavioralpupil near response
06

What researchers measure

Primary outcomes

  1. Each group's proportion of MCS patients diagnosed by CRS-R in the follow up

    Greater proportion in PNR+ group suggests PNR has prognostic value to DOC patients thus has relationship with consciousness

    Time frame: 3 months after pupil near response assessment in this study

Secondary outcomes

  1. Each group's proportion of recovery of conscious visual function diagnosed by visual subscale of CRS-R in the follow up

    Greater proportion in PNR+ group suggests PNR can correct misdiagnosis caused by lesions on motor systems thus is applicable to patients without motor function

    Time frame: 3 months after pupil near response assessment in this study

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Feb 2016, 3 months.

Of 16 observational studies under Persistent Vegetative State, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2016
First posted
Jul 14, 2016
StartActual
Oct 29, 2015
Primary completionActual
Feb 10, 2016
CompletionActual
Feb 10, 2016
Last update
Aug 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02832492
Lead sponsor
Wentao Zeng
Responsible party
Wentao Zeng (Master degree candidate, Hangzhou Normal University) — Sponsor-investigator
First posted
Jul 14, 2016
Start date
Oct 29, 2015
Primary completion
Feb 10, 2016
Completion
Feb 10, 2016
Last update
Aug 4, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion